ArticleEpilepsia open2026
A randomized controlled trial of a multimodality digital health intervention to aid the delivery of the modified ketogenic diet therapy for epilepsy: The Keto eCoach trial protocol.
Article in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
objectiveDietary therapy is an effective treatment for drug-resistant epilepsy; however, low adherence presents a significant barrier to use in the clinical setting. This study aims to evaluate a multimodality digital health intervention to overcome this barrier and improve outcomes in adults undertaking the modified ketogenic diet for epilepsy.
methodThis is a two-arm, randomized, controlled trial. A total of 136 participants will be randomized 1:1 to receive the modified ketogenic diet as per standard clinical care, or with the addition of the multimodality digital health intervention for 12 weeks. The intervention will include three components: (1) digital diaries, (2) a novel, at-home, saliva-based ketone testing device, and (3) dynamic dietitian support.
resultsThe primary treatment benefit will be determined using the epilepsy desirability of outcome rank, a composite outcome measure co-designed with people living with drug-resistant epilepsy. Secondary outcomes will include seizure frequency, treatment retention, adverse events, psychiatric symptoms, quality of life, medication use, cost effectiveness, and acceptability of the intervention. SIGNIFICANCE: The results of this trial will provide evidence on the effectiveness of using this innovative digital health intervention approach to improve treatment outcomes of dietary therapy for drug-resistant epilepsy. ETHICS AND DISSEMINATION: This study has received approval from the Alfred Hospital Human Research Ethics Committee (Reference No.: 723/23). The results will be disseminated via peer-reviewed publications and publicly available plain language summaries. TRIAL REGISTRATION NUMBER: Australian New Zealand Clinical Trials Registry (ANZCTR, ACTRN12624000486527). PLAIN LANGUAGE SUMMARY: This trial aims to find out if a 12-week digital health program can improve treatment outcomes of people living with epilepsy. We will invite 136 people commencing on the modified ketogenic diet to be randomly assigned to the digital health program or standard clinic care. The treatment outcome will be assessed combining seizure frequency, side effects, and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.